Effect of Foeniculum vulgare Mill. (fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial.

OBJECTIVE: Preliminary data suggest that Foeniculum vulgare (fennel) can be an effective treatment for menopausal symptoms. This trial was designed to assess the efficacy of fennel in the management of menopausal symptoms in postmenopausal women. METHODS: In this triple-blind, placebo-controlled trial, 90 postmenopausal women aged 45 to 60 years in Tehran were randomly assigned to treatment (n = 45) or placebo (n = 45) groups. The participants received 8 weeks of treatment with soft capsules containing 100 mg fennel or a placebo (2 per day for each group). The participants were followed for 2 weeks postintervention to assess the continuance of the effect of intervention. The Menopause Rating Scale (MRS) questionnaire was used to assess changes in menopausal symptoms at baseline and at 4, 8, and 10 weeks after onset of intervention. RESULTS: The groups recorded similar mean scores on the MRS questionnaire before intervention. After intervention, the treatment group showed a significant decrease in the mean MRS score. The results of the Friedman test showed significant differences between the mean score at baseline and those at 4, 8, and 10 weeks after onset of intervention in the treatment group (P < 0.001), whereas there were no significant differences in the placebo group. When the fennel and the placebo groups were compared, the independent t test showed significant differences in mean scores between groups at 4, 8, and 10 weeks (2 weeks postintervention; P < 0.001). CONCLUSIONS: Fennel is an effective and safe treatment to reduce menopausal symptoms in postmenopausal women without serious side effects. More clinical trials with larger populations are required to confirm this result.

Comparison of halogen light and vibroacoustic stimulation on nonreactive fetal heart rate pattern.

BACKGROUND: One of the first-line assessment tools for fetal surveillance is nonstress test (NST), although it is limited by a high rate of false-nonreactive results. This study was performed to investigate if external stimulation from vibroacoustic and halogen light could help in provoking fetal responsiveness and altering NST results. MATERIALS AND METHODS: This is a clinical trial. Sampling was done from April to July 2010. One hundred pregnant women with nonreactive NST for 20 min were allocated in two groups: Vibroacoustic stimulated NST (VNST, n = 50) who received vibration from a standard fetal vibratory stimulator and halogen light stimulated NST (LNST, n = 50) who received a halogen light source for 3 and 10 sec, respectively. Results were compared together and then compared to biophysical profile (BPP) scores as a backup test. We used Mann-Whitney U test, Chi-square test, and Fisher's exact test to compare the variables in the two groups through SPSS version 14. P < 0.05 was considered as statistically significant. RESULTS: Following stimulations, 68% nonreactive subjects in halogen light stimulation group and 62% in vibroacoustic stimulation group changed to reactive patterns. Time to onset of the first acceleration (VNST: 2.17 min; LNST: 2.27 min) and the test duration (VNST: 4.91 min; LNST: 5.26 min) were the same in the two groups. In VNST 89.5% and in LNST 87.5% of nonreactivity followed by score 8 in BPP. There was no significant relation between stimulus NSTs and BPPs. CONCLUSION: Vibroacoustic and light stimulation offer benefits by decreasing the incidence of nonreactive results and reducing the test time. Both halogen light stimulation and vibroacoustic stimulation are safe and efficient in fetal well-being assessment services.